We want to challenge and improve today's standardized treatments with the help of our AI-Immunology™ platform. In the field of oncology, we create truly personalized therapies where one size fits one, and only one. Within infectious diseases, we use the technology to design next-generation vaccines to address unmet medical needs.
Evaxion's pioneering AI-Immunology™ platform accelerates fast and effective vaccine target discovery, design, and development. Using the power of AI, our platform simulates the human immune system and generates predictive models to identify and develop personalized and other next-generation immunotherapies for patients.
A broad pipeline of unique, world-class candidates with the potential to revolutionize the prevention and treatment of cancer and infectious disease. Our AI-Immunology™ platform enables a high level of scalability, offering the potential to expand our portfolio and our proprietary platforms to the benefit of patients worldwide.
At the forefront of biotechnological innovation, our cutting-edge research is dedicated to advancing vaccine immunotherapies to battle cancer and infectious diseases. With a wide range of multidisciplinary capabilities, our research allows for continuous iterative learning loops which accelerates the development of transformative treatments and significantly enhance the value of our platform.
Since 2021, Evaxion has been listed on the Nasdaq Capital Market exchange (ticker code: EVAX). Here you can find all of the latest Evaxion investor insights: our results, upcoming events and news, important shareholder updates and much more.
We believe collaborating with leading and like-minded partners will create the best-in-class vaccines for patients. Our business model is geared toward a multi-partner approach focused around single or multiple vaccine target discovery, design and development agreements
Stay informed with Evaxion’s latest press releases, events, scientific posters and publications, and media resources.
